Cargando…

Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age?

In vitro maturation of oocytes from antral follicles seen during tissue harvesting is a fertility preservation technique with potential advantages over ovarian tissue cryopreservation (OTC), as mature frozen and later thawed oocyte used for fertilization poses decreased risk of malignant cells re-se...

Descripción completa

Detalles Bibliográficos
Autores principales: Karavani, Gilad, Wasserzug-Pash, Peera, Mordechai-Daniel, Talya, Bauman, Dvora, Klutstein, Michael, Imbar, Tal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250136/
https://www.ncbi.nlm.nih.gov/pubmed/34222236
http://dx.doi.org/10.3389/fcell.2021.667682
_version_ 1783717026301214720
author Karavani, Gilad
Wasserzug-Pash, Peera
Mordechai-Daniel, Talya
Bauman, Dvora
Klutstein, Michael
Imbar, Tal
author_facet Karavani, Gilad
Wasserzug-Pash, Peera
Mordechai-Daniel, Talya
Bauman, Dvora
Klutstein, Michael
Imbar, Tal
author_sort Karavani, Gilad
collection PubMed
description In vitro maturation of oocytes from antral follicles seen during tissue harvesting is a fertility preservation technique with potential advantages over ovarian tissue cryopreservation (OTC), as mature frozen and later thawed oocyte used for fertilization poses decreased risk of malignant cells re-seeding, as compared to ovarian tissue implantation. We previously demonstrated that in vitro maturation (IVM) performed following OTC in fertility preservation patients, even in pre-menarche girls, yields a fair amount of oocytes available for IVM and freezing for future use. We conducted a retrospective cohort study, evaluating IVM outcomes in chemotherapy naïve patients referred for fertility preservation by OTC that had oocyte collected from the medium with attempted IVM. A total of 133 chemotherapy naïve patients aged 1–35 years were included in the study. The primary outcome was IVM rate in the different age groups – pre-menarche (1–5 and ≥6 years), post-menarche (menarche-17 years), young adults (18–24 years) and adults (25–29 and 30–35 years). We demonstrate a gradual increase in mean IVM rate in the age groups from 1 to 25 years [4.6% (1–5 years), 23.8% (6 years to menarche), and 28.4% (menarche to 17 years)], with a peak of 38.3% in the 18–24 years group, followed by a decrease in the 25–29 years group (19.3%), down to a very low IVM rate (8.9%) in the 30–35 years group. A significant difference in IVM rates was noted between the age extremes – the very young (1–5 years) and the oldest (30–35 years) groups, as compared with the 18–24-year group (p < 0.001). Importantly, number of oocytes matured, percent of patients with matured oocytes, and overall maturation rate differed significantly (p < 0.001). Our finding of extremely low success rates in those very young (under 6 years) and older (≥30 years) patients suggests that oocytes retrieved during OTC prior to chemotherapy have an optimal window of age that shows higher success rates, suggesting that oocytes may have an inherent tendency toward better maturation in those age groups.
format Online
Article
Text
id pubmed-8250136
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82501362021-07-03 Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age? Karavani, Gilad Wasserzug-Pash, Peera Mordechai-Daniel, Talya Bauman, Dvora Klutstein, Michael Imbar, Tal Front Cell Dev Biol Cell and Developmental Biology In vitro maturation of oocytes from antral follicles seen during tissue harvesting is a fertility preservation technique with potential advantages over ovarian tissue cryopreservation (OTC), as mature frozen and later thawed oocyte used for fertilization poses decreased risk of malignant cells re-seeding, as compared to ovarian tissue implantation. We previously demonstrated that in vitro maturation (IVM) performed following OTC in fertility preservation patients, even in pre-menarche girls, yields a fair amount of oocytes available for IVM and freezing for future use. We conducted a retrospective cohort study, evaluating IVM outcomes in chemotherapy naïve patients referred for fertility preservation by OTC that had oocyte collected from the medium with attempted IVM. A total of 133 chemotherapy naïve patients aged 1–35 years were included in the study. The primary outcome was IVM rate in the different age groups – pre-menarche (1–5 and ≥6 years), post-menarche (menarche-17 years), young adults (18–24 years) and adults (25–29 and 30–35 years). We demonstrate a gradual increase in mean IVM rate in the age groups from 1 to 25 years [4.6% (1–5 years), 23.8% (6 years to menarche), and 28.4% (menarche to 17 years)], with a peak of 38.3% in the 18–24 years group, followed by a decrease in the 25–29 years group (19.3%), down to a very low IVM rate (8.9%) in the 30–35 years group. A significant difference in IVM rates was noted between the age extremes – the very young (1–5 years) and the oldest (30–35 years) groups, as compared with the 18–24-year group (p < 0.001). Importantly, number of oocytes matured, percent of patients with matured oocytes, and overall maturation rate differed significantly (p < 0.001). Our finding of extremely low success rates in those very young (under 6 years) and older (≥30 years) patients suggests that oocytes retrieved during OTC prior to chemotherapy have an optimal window of age that shows higher success rates, suggesting that oocytes may have an inherent tendency toward better maturation in those age groups. Frontiers Media S.A. 2021-06-18 /pmc/articles/PMC8250136/ /pubmed/34222236 http://dx.doi.org/10.3389/fcell.2021.667682 Text en Copyright © 2021 Karavani, Wasserzug-Pash, Mordechai-Daniel, Bauman, Klutstein and Imbar. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Karavani, Gilad
Wasserzug-Pash, Peera
Mordechai-Daniel, Talya
Bauman, Dvora
Klutstein, Michael
Imbar, Tal
Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age?
title Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age?
title_full Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age?
title_fullStr Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age?
title_full_unstemmed Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age?
title_short Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age?
title_sort age-dependent in vitro maturation efficacy of human oocytes – is there an optimal age?
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250136/
https://www.ncbi.nlm.nih.gov/pubmed/34222236
http://dx.doi.org/10.3389/fcell.2021.667682
work_keys_str_mv AT karavanigilad agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage
AT wasserzugpashpeera agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage
AT mordechaidanieltalya agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage
AT baumandvora agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage
AT klutsteinmichael agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage
AT imbartal agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage